It will be important that these and future human trials of anti-VISTA monoclonal antibodies and small molecule VISTA inhibitors include correlative studies on which different TME landscapes are most responsive to therapy; this will require biomarker-focused clinical trials with tumor biopsies before and after treatment. The gene discussed is VSIR; the disease is neoplasm.